Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
Susan E. Krown(Memorial Sloan Kettering Cancer Center), Seán McCarthy, Marije Van Schalkwyk, Mina C. Hosseinipour, Taylor Harrison(Emory University), Thomas Campbell(University of Colorado Anschutz Medical Campus), Stephanie Caruso(Frontier Science & Technology Research Foundation, Inc.), Catherine Godfrey(United States Department of State), Carlee Moser(Harvard University), Jessica O'Connell-Maritz, Henriette Burger(Stellenbosch University), Annet Nakaganda, Margaret Borok(University of Zimbabwe), P Cheruiyot, Katherine Shin, Lynne Cornelissen, Wadzanai Samaneka(University of Zimbabwe), Naftali Busakhala(Moi University), Minenhle Ngcobo, Iveshni Govender, Felluna Chauwa, Lara Hosey(Social and Scientific Systems (United States)), Jeannette Y. Lee(University of Arkansas at Little Rock), Patrick MacPhail(University of the Witwatersrand), Pamela Mukwekwerere(University of Zimbabwe), Brenda Hoagland(Fundação Oswaldo Cruz), William Wachsman, Clement Dove Okello, Winnie Keter, Irene Kutto, Tamiris Baião, Ivy Gudza, Mostafa Nokta(National Institutes of Health), John Okanda, Rejoice Sikhosana, Noluthando Mwelase(University of the Witwatersrand), Vincent O Oliver(Kenya Medical Research Institute), Mulinda Nyirenda(University of Malawi), Godwin Ulaya, Josphat Kosgei(United States Army Medical Research Directorate - Africa), Roy M. Matining(Cancer Research And Biostatistics), Rosie Mngqibisa, Agnes Moses, Cecilia Kanyama, Scott Evans, Jennifer Rothenberg, Fred Okuku(Uganda Cancer Institute), Geoffrey Koskei, Kevin P. Cain, Juliana dos Santos Barbosa Netto
Cited by 91
Related Papers
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
|New England Journal of Medicine|2021|548
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|540
Alterations in the Gut Microbiota Associated with HIV-1 Infection
|Cell Host & Microbe|2013|508